28199-56-6

Usage

Chemical Family

Purine

Derivative of

Nucleotide adenine

Type of Compound

Heterocyclic

Ring Structure

Purine ring

Asymmetry

Introduced by a methyl group at the sixth position

Functional Group

1-oxide

Reactivity

Increased by the presence of the 1-oxide functional group

Usage

Pharmaceutical research and as a building block for the synthesis of biologically active compounds

Potential

Important molecule in the development of new drugs and medicinal compounds

Source

Material provided

InChI:InChI=1/C6H7N4O/c1-4-5-6(8-2-7-5)9-3-10(4)11/h2-5H,1H3/q+1

Upstream product

• 2004-03-7 6-methylpurine 
• 7306-68-5 6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 

Relevant academic research and scientific papers

IMIDAZOTETRAZINE COMPOUNDS

New synthetic methods to provide access to previously unexplored functionality at the C8 position of imidazotetrazines. Through synthesis and evaluation of a suite of compounds with a range of aqueous stabilities (from 0.5 to 40 hours), a predictive model for imidazotetrazine hydrolytic stability based on the Hammett constant of the C8 substituent was derived. Promising compounds were identified that possess activity against a panel of GBM cell lines, appropriate hydrolytic and metabolic stability, and brain-to-serum ratios dramatically elevated relative to TMZ, leading to lower hematological toxicity profiles and superior activity to TMZ in a mouse model of GBM.

Methyltrioxorhenium (MeReO3) catalyzed selective oxidation of purine and related compounds into their N-oxides

A convenient method for the selective N-oxidation of purine, 6-methylpurine, 1H-imidazo[4,5-c]pyridine, 1H-imidazo[4,5-b]pyridine, 6-chloropurine, 6-bromopurine, and 7-azaindole by H2O2 catalyzed by methyltrioxorhenium is reported.